GlassScriptPhysician profile
Tarik H Hadid
NPI 1144424623
$8,073.72
in general payments reported to CMS, 2019-2025
21 companies · $88.71 in 2025
The $88.71 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $2,850 · 2021: $4,663 · 2024: $82.08 · 2025: $88.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $170.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $3,162.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,850.00 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $1,500.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $106.45 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $99.00 | 2019 | |
| Agios Pharmaceuticals, INC. | $61.60 | 2024-2025 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $47.28 | 2019 | |
| Pfizer INC. | $43.38 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.89 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $21.76 | 2019 | |
| Springworks Therapeutics, INC. | $20.73 | 2024 | Ogsiveo |
| Amgen INC. | $20.25 | 2019 | |
| Abbvie INC. | $19.92 | 2019 | |
| Exelixis INC. | $17.82 | 2019 | |
| Terumo Bct, INC. | $17.56 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.38 | 2025 | Ojjaara |
| Merck Sharp & Dohme LLC | $13.84 | 2019 | |
| Genentech USA, INC. | $12.82 | 2019 | |
| Gilead Sciences, INC. | $12.54 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarik Hadid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.